
News|Videos|September 11, 2025
Stay Updated on AI Chatbots With a New Series From Allen Frances, MD
Author(s)Allen Frances, MD
Allen Frances, MD, introduces his new weekly series for Psychiatric Times: “AI Chatbots: The Good, the Bad, and the Ugly.”
Advertisement
Advertisement
Allen Frances, MD, chair emeritus of Duke University’s Department of Psychiatry and former chair of the DSM-IV Task Force, introduces his new weekly series for Psychiatric Times: “AI Chatbots: The Good, the Bad, and the Ugly.” This timely and thought-provoking series explores how artificial intelligence chatbots are impacting psychiatry, offering both unprecedented opportunities and profound risks. Articles in the series will be posted to Psychiatric Times every Tuesday; read the articles already posted from this series
Related to this article

Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.

Ketamine, esketamine, and ECT can rapidly ease suicidal thoughts, but evidence for preventing attempts or deaths remains limited—see what’s proven.

Learn how clozapine, lithium, ketamine, and antidepressants fit into suicide prevention, from rapid crisis relief to long-term risk reduction.

Can hormones flag suicide risk in schizophrenia? Review links cortisol, thyroid and testosterone shifts—and clozapine/lithium pathways—to risk.
Advertisement
Advertisement

